Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CStone to Start China Trial of its MEK Inhibitor

publication date: Jul 30, 2018

CStone Pharma of Suzhou reported that its China IND application for CS3006, a small-molecule MEK inhibitor, has been approved. One month ago, CStone dosed the first patient in an Australian trial of the candidate. The company says the MEK inhibitor showed strong pharmacokinetic properties in preclinical testing, with synergistic activity when combined with the CStone's PD-1 candidate. In May, CStone raised a record $260 million in a Series B round. The company has ten oncology drug candidates in development. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital